Aurobindo Pharma's shares rose 2% after the US FDA completed an inspection of its subsidiary's API manufacturing facility with two procedural observations. The company reported an 8.6% YoY rise in Q2 FY25 net profit to Rs 817 crore, driven by strong European and growth market sales. Revenue increased 8% YoY to Rs 7,796 crore.
